These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11734111)

  • 81. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
    Sousa SF; Fernandes PA; Ramos MJ
    Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
    Ohkanda J
    Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
    [No Abstract]   [Full Text] [Related]  

  • 88. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Farnesyl transferase inhibitors--a novel therapy for breast cancer.
    Johnston SR; Kelland LR
    Endocr Relat Cancer; 2001 Sep; 8(3):227-35. PubMed ID: 11566614
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
    Omer CA; Anthony NJ; Buser-Doepner CA; Burkhardt AL; deSolms SJ; Dinsmore CJ; Gibbs JB; Hartman GD; Koblan KS; Lobell RB; Oliff A; Williams TM; Kohl NE
    Biofactors; 1997; 6(3):359-66. PubMed ID: 9288406
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
    Pan J; Yeung SC
    Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.
    Manne V; Lee FY; Bol DK; Gullo-Brown J; Fairchild CR; Lombardo LJ; Smykla RA; Vite GD; Wen ML; Yu C; Wong TW; Hunt JT
    Cancer Res; 2004 Jun; 64(11):3974-80. PubMed ID: 15173010
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
    Gotlib J
    Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2005; 22():123-33. PubMed ID: 16110610
    [No Abstract]   [Full Text] [Related]  

  • 98. Ras inhibitors and radiation therapy.
    Jones HA; Hahn SM; Bernhard E; McKenna WG
    Semin Radiat Oncol; 2001 Oct; 11(4):328-37. PubMed ID: 11677657
    [TBL] [Abstract][Full Text] [Related]  

  • 99. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
    Mahgoub N; Taylor BR; Gratiot M; Kohl NE; Gibbs JB; Jacks T; Shannon KM
    Blood; 1999 Oct; 94(7):2469-76. PubMed ID: 10498620
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
    Lancet JE; Rosenblatt JD; Karp JE
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):31-5. PubMed ID: 12214291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.